We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Lumera Scientist Previews Company's Therapeutic Antibody Drug Discovery Products
News

Lumera Scientist Previews Company's Therapeutic Antibody Drug Discovery Products

Lumera Scientist Previews Company's Therapeutic Antibody Drug Discovery Products
News

Lumera Scientist Previews Company's Therapeutic Antibody Drug Discovery Products

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Lumera Scientist Previews Company's Therapeutic Antibody Drug Discovery Products"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Lumera Corporation, Surface Scientist Christina Boozer, Ph.D., has presented a research poster describing the company's proprietary technology and product development activities relating to therapeutic antibody drug discovery at the Annual Meeting of the Society for Biomolecular Sciences.

The presentation detailed the analysis of a high density antibody microarray for potential drug discovery "hits" to the cancer antigen Carcino Embryonic Antigen (CEA).

Using the ProteomicProcessor™ and NanoCapture™ microarrays , Lumera scientists demonstrated a method by which various antibodies specific to CEA can be detected.

"Dr. Boozer's presentation was well received by researchers in attendance, specifically those looking for new tools and applications which provide specificity profiling in a high throughput, label free format," said the Director of Lumera's Bioscience Unit Dr. Tim Londergan.

"With the presentation of this research poster, we are paving the way for the commercial launch of the ProteomicProcessor™ in early next year, which will be targeted at the therapeutic antibody market."

Advertisement